PRECLINICAL EVALUATION OF INTERMEDIATE ENDPOINTS AND THEIR MODULATIONBY CHEMOPREVENTIVE AGENTS NIH GUIDE, Volume 23, Number 7, February 18, 1994 RFP AVAILABLE: NCI-CN-45594-32 P.T. 34 Keywords: Cancer/Carcinogenesis Disease Model Chemopreventive Agents Biological Markers National Cancer Institute The National Cancer Institute is seeking contractors qualified to perform animal cancer model studies of biomarkers and intermediate endpoints that might be used in human clinical trials. The work to be performed will assess, in detail, the biomarker modulating effects of selected chemopreventive compounds. This solicitation is an annual announcement to expand a current pool of Master Agreement (MA) Holders qualified to perform this type of work. Individual work requirements will be defined as the need arises by Master Agreement Orders issued during the period of performance, and Master Agreement Orders will be awarded based on competition between members of the MA pool. The solicitation will be released on or about February 22, 1994 with proposals due April 23, 1994. INQUIRIES The Contracting Officer for this solicitation is Richard L. Hartmann on telephone (301) 496-8603. Copies of the RFP may be obtained by sending a written request to: Ms. Desiree Sylver-Foust Research Contracts Branch National Cancer Institute Executive Plaza South, Room 635 Bethesda, MD 20892 Telephone: (301) 496-8603 .
Return to NIH Guide Main Index
Office of Extramural Research (OER) |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
Department of Health and Human Services (HHS) |
||||||||
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files. |